InVivo Therapeutics

InVivo Therapeutics is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. The Company's mission is to redefine the life of the SCI patient, and it is developing treatment options intended to provide meaningful improvement in patient outcomes following SCI. InVivo's approach to treating acute SCIs is based on our investigational Neuro-Spinal Scaffold implant, a bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord and is intended to treat acute SCI.

Company Growth (employees)
Type
Public
HQ
Cambridge, US
Founded
2005
Size (employees)
37 (est)+24%
InVivo Therapeutics was founded in 2005 and is headquartered in Cambridge, US

Key People at InVivo Therapeutics

Mark Perrin

Mark Perrin

CEO/Director
Kenneth DiPietro

Kenneth DiPietro

Director
Christopher McNulty

Christopher McNulty

Vice President, Business Development

InVivo Therapeutics Office Locations

InVivo Therapeutics has an office in Cambridge
Cambridge, US (HQ)
1 Kendall Square

InVivo Therapeutics Data and Metrics

InVivo Therapeutics Financial Metrics

USD

Net income (Q1, 2017)

(6.4 m)

EBIT (Q1, 2017)

(6.7 m)

Market capitalization (25-Jul-2017)

70.6 m

Cash (31-Mar-2017)

14.4 m
InVivo Therapeutics's current market capitalization is $70.6 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016

R&D expense

10.5 m10.3 m10.1 m12.6 m

General and administrative expense

8.5 m7.6 m12.3 m11.5 m

Operating expense total

19 m17.8 m22.4 m24.1 m

EBIT

(19 m)(17.8 m)(22.4 m)(24.1 m)

Interest expense

(129.9 k)(136 k)(172 k)(155 k)

Interest income

15.3 k5 k60 k187 k

Net Income

(38.8 m)(18.3 m)(33.3 m)(23.4 m)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

R&D expense

3.1 m2.4 m2.3 m2.5 m2.4 m2.6 m2.8 m3.3 m3.4 m

General and administrative expense

1.7 m1.8 m3.2 m3.2 m3.4 m3 m3 m2.6 m3.3 m

Operating expense total

4.7 m4.2 m5.5 m5.8 m5.9 m5.6 m5.8 m5.9 m6.7 m

EBIT

(4.7 m)(4.2 m)(5.5 m)(5.8 m)(5.9 m)(5.6 m)(5.8 m)(5.9 m)(6.7 m)

Interest expense

(35 k)(35 k)(34 k)(32 k)(32 k)(63 k)(29 k)(32 k)(20 k)

Interest income

1 k2 k1 k2 k2 k54 k36 k50 k57 k

Net Income

(8.7 m)(10 m)(15.8 m)(26.3 m)(28.6 m)(6.6 m)(11.8 m)(18 m)(6.4 m)
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

14 m13.5 m20.2 m21.5 m

Accounts Receivable

222 m

Inventories

20.1 k1.1 m184 k451 k

Current Assets

14.6 m15 m20.7 m33.9 m

PP&E

2.3 m1.6 m938 k510 k

Total Assets

17.1 m16.7 m21.8 m34.8 m

Accounts Payable

899.3 k569 k521 k1 m

Current Liabilities

2.3 m9.2 m3.3 m4.8 m

Total Liabilities

5.8 m

Additional Paid-in Capital

94.8 m106.2 m150.5 m186 m

Retained Earnings

(100.3 m)(133.6 m)(157 m)

Total Equity

12.9 m5.9 m16.9 m28.9 m

Financial Leverage

1.3 x2.8 x1.3 x1.2 x
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

20.9 m17.6 m24.5 m25.1 m22.1 m45.8 m41.6 m37.7 m14.4 m

Current Assets

21.6 m18.3 m25.4 m25.9 m22.8 m46.7 m42.7 m38.4 m27.4 m

Total Assets

23.7 m20.3 m27 m27.3 m24 m47.7 m43.5 m39.5 m29 m

Accounts Payable

592 k711 k793 k953 k797 k438 k559 k556 k1 m

Current Liabilities

7.8 m4.8 m15.1 m10.3 m5.5 m4.8 m4.6 m5.5 m4.1 m

Additional Paid-in Capital

104.7 m105.4 m126.3 m141.8 m145.9 m181.7 m183 m184.4 m187.5 m

Retained Earnings

(116.1 m)(126.5 m)(128.8 m)(140.2 m)(145.4 m)(151.6 m)(163.6 m)

Total Equity

14 m13.6 m10.3 m15.3 m17.1 m41.5 m37.6 m32.8 m24 m

Financial Leverage

1.7 x1.5 x2.6 x1.8 x1.4 x1.1 x1.2 x1.2 x1.2 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(38.8 m)(18.3 m)(33.3 m)(23.4 m)

Depreciation and Amortization

740.7 k752 k689 k553 k

Accounts Payable

(253.3 k)(330 k)(48 k)489 k

Cash From Operating Activities

(14.9 m)(15.3 m)(16.3 m)(16.7 m)

Purchases of PP&E

(748.5 k)(47 k)(5 k)(107 k)

Cash From Investing Activities

(748.5 k)(2 k)(5 k)(6.5 m)

Cash From Financing Activities

16.8 m14.8 m23.1 m29.8 m

Interest Paid

125.3 k132 k121 k103 k
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(8.7 m)(10 m)(15.8 m)(26.3 m)(28.6 m)(6.6 m)(11.8 m)(18 m)(6.4 m)

Depreciation and Amortization

378 k568 k178 k352 k527 k146 k284 k417 k135 k

Accounts Payable

(307 k)(188 k)224 k384 k228 k(83 k)38 k35 k27 k

Cash From Operating Activities

(7.8 m)(11.1 m)(2.9 m)(7.1 m)(11 m)(4.2 m)(8.3 m)(12.3 m)(6.1 m)

Purchases of PP&E

(5 k)(14 k)(35 k)(5 k)(2 k)(50 k)(73 k)(96 k)(16 k)

Cash From Investing Activities

(5 k)(14 k)(35 k)(5 k)(2 k)(50 k)(73 k)(96 k)(827 k)

Cash From Financing Activities

14.7 m14.7 m14 m18.8 m19.7 m29.9 m29.8 m29.9 m(57 k)

Interest Paid

65 k77 k33 k64 k97 k28 k54 k76 k20 k
Y, 2017

Financial Leverage

1.2 x

InVivo Therapeutics Operating Metrics

InVivo Therapeutics's Facilities was reported to be 1 in FY, 2016
FY, 2016

Patents (foreign)

8

Patents (US)

8

Patents Pending

12

Facilities

1

InVivo Therapeutics Market Value History

InVivo Therapeutics Online and Social Media Presence

InVivo Therapeutics Company Life and Culture

You may also be interested in